{
    "clinical_study": {
        "@rank": "139681", 
        "arm_group": {
            "arm_group_label": "Enzalutamide, Leuprolide, radiation", 
            "arm_group_type": "Other", 
            "description": "Single arm Enzalutamide 160 mg daily for 6 months Leuprolide acetate 22.5mg every 3 months or 45mg every 6 months Radiation therapy as standard of care"
        }, 
        "brief_summary": {
            "textblock": "The study is being done to find out whether combining two FDA approved drugs along with\n      radiation therapy for the treatment of high risk localized prostate cancer is safe and well\n      tolerated."
        }, 
        "brief_title": "Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer", 
        "completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "-  this pilot study will assess the safety and tolerability of combining enzalutamide with\n           an gonadotropin-releasing hormone agonist (GnRH) and external beam radiation\n\n        -  Correlative imaging and tissue biopsy analysis will be performed to assess the\n           radiographic response to enzalutamide plus gonadotropin-releasing hormone agonist\n           (GnRH) therapy as well as intratumoral androgen signaling"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically proven adenocarcinoma of the prostate within 6 months of screening\n\n          -  Eastern Cooperative Oncology Group(ECOG) score 0-2\n\n          -  adequate organ and and blood marrow function\n\n          -  must be a candidate for long-term androgen deprivation in combination with external\n             beam radiation for the treatment of high risk prostate cancer\n\n          -  patient must permit a targeted prostate biopsy at the time of study initiation or at\n             the beginning of radiation treatment\n\n          -  men who are sexually active with female partners of child-bearing potential mush\n             agree to use adequate contraception\n\n        Exclusion Criteria:\n\n          -  prior treatment with agents known to have endocrine effects on prostate cancer\n\n          -  treatment with corticosteroids within 4 weeks of enrollment\n\n          -  treatment with androgens within 6 months of enrollment\n\n          -  may not be receiving any other investigational agents\n\n          -  Prostate specific antigen greater than 160ng/dL\n\n          -  history of malignancy( other than non-melanoma skin cancer) within 5 years\n\n          -  uncontrolled intercurrent illness\n\n          -  cardiovascular event within 6 months of enrollment\n\n          -  seizure or seizure disorder history\n\n          -  contraindications to MRI- pacemakers, clips, etc"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02064582", 
            "org_study_id": "082013-032"
        }, 
        "intervention": [
            {
                "arm_group_label": "Enzalutamide, Leuprolide, radiation", 
                "description": "160mg by mouth each day", 
                "intervention_name": "Enzalutamide", 
                "intervention_type": "Drug", 
                "other_name": "Xtandi"
            }, 
            {
                "arm_group_label": "Enzalutamide, Leuprolide, radiation", 
                "description": "22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months", 
                "intervention_name": "Leuprolide acetate", 
                "intervention_type": "Drug", 
                "other_name": "Lupron"
            }, 
            {
                "arm_group_label": "Enzalutamide, Leuprolide, radiation", 
                "description": "External beam radiation will be delivered as per standard radiation therapy protocol", 
                "intervention_name": "radiation", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Leuprolide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "prostate cancer, enzalutamide, radiation, hormone therapy", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "Allison.Beaver@utsouthwestern.edu", 
                "last_name": "Allison Beaver, RN, BSN", 
                "phone": "214-645-8787"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75390"
                }, 
                "name": "UT Southwestern Medical Center"
            }, 
            "investigator": {
                "last_name": "Kevin D Courtney, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Study of Enzalutamide and GnRH Agonist Before, During and After Radiation Therapy in Treatment of Patients With High-risk Localized Prostate Cancer", 
        "overall_contact": {
            "email": "Allison.Beaver@utsouthwestern.edu", 
            "last_name": "Allison Beaver, RN, BSN", 
            "phone": "214-645-8787"
        }, 
        "overall_official": {
            "affiliation": "UT Southwestern Medical Center", 
            "last_name": "Kevin D Courtney, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment will be based on the rate of drug related grade 1-5 adverse events experienced within the first 12 months of study treatment via NCI Common terminology criteria for adverse events(CTCAE) v4.0", 
            "measure": "Assess the safety and tolerability of combining enzalutamide with a GnRH and external beam radiation", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02064582"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "tumor gene expression will be analyzed on tissue samples pre and post therapy", 
            "measure": "Assess intra-tumoral androgen regulated gene expression pre and post combination therapy", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma US, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}